Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Hanns-Christian Tillmann"'
Autor:
Dave Singh, Jim M. Wild, Dinesh Saralaya, Rod Lawson, Helen Marshall, Jonathan Goldin, Matthew S. Brown, Konstantinos Kostikas, Kristin Belmore, Robert Fogel, Francesco Patalano, Anton Drollmann, Surendra Machineni, Ieuan Jones, Denise Yates, Hanns-Christian Tillmann
Publikováno v:
Respiratory Research, Vol 23, Iss 1, Pp 1-12 (2022)
Abstract Rationale The long-acting β2-agonist/long-acting muscarinic antagonist combination indacaterol/glycopyrronium (IND/GLY) elicits bronchodilation, improves symptoms, and reduces exacerbations in COPD. Magnetic resonance imaging (MRI) of the l
Externí odkaz:
https://doaj.org/article/e3368be44640402a8dae82c0bbe15e33
Autor:
Satoru Inoue, Soniya Vaidya, Hanns-Christian Tillmann, Yohei Sakita, Surendra Machineni, Olivier Heudi, Kenichi Furihata
Publikováno v:
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background A once-daily (o.d.) fixed-dose combination of indacaterol acetate (IND), glycopyrronium bromide (GLY), and mometasone furoate (MF) delivered via the Breezhaler® device (IND/GLY/MF) is being developed for treatment of asthma. This
Externí odkaz:
https://doaj.org/article/4122474c4b0a416fb9601633b91a9840
Autor:
David Miller, Soniya Vaidya, Juergen Jauernig, Brian Ethell, Kristina Wagner, Rajkumar Radhakrishnan, Hanns-Christian Tillmann
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-9 (2020)
Abstract Background Indacaterol maleate delivered with the Breezhaler® inhalation device is a long-acting β2-agonist approved for chronic obstructive pulmonary disease. In the development of a once daily, inhaled fixed dose combination (FDC) of ind
Externí odkaz:
https://doaj.org/article/1a920b11827a46acb6998035fe0d4194
Autor:
Henrik Watz, Jens M. Hohlfeld, Dave Singh, Jutta Beier, Zuzana Diamant, Jinming Liu, Shucheng Hua, Khalid Abd-Elaziz, Pascale Pinot, Ieuan Jones, Hanns-Christian Tillmann
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-5 (2020)
Abstract Indacaterol (IND; 150 μg), glycopyrronium (GLY; 50 μg) and mometasone furoate (MF; 160 μg [high-dose ICS] and 80 μg [medium-dose ICS]) have been formulated as a once-daily (o.d.) fixed-dose combination treatment delivered via the Breezha
Externí odkaz:
https://doaj.org/article/d541d016783b409fa448e2abf8959460
Autor:
Jutta Beier, Henrik Watz, Zuzana Diamant, Jens M. Hohlfeld, Dave Singh, Pascale Pinot, Ieuan Jones, Hanns-Christian Tillmann
Publikováno v:
ERJ Open Research, Vol 7, Iss 2 (2021)
Once-daily asthma treatment should prevent night-time deterioration, irrespective of the time of dosing. IND/GLY/MF, a fixed-dose combination of inhaled indacaterol acetate (IND, long-acting β2-agonist (LABA)), glycopyrronium bromide (GLY, long-acti
Externí odkaz:
https://doaj.org/article/99699244ff954991a421dbce4bd5f2b0
Autor:
Wolf-Georg Forssmann, Hanns-Christian Tillmann, Dieter Hock, Kristin Forssmann, Corrado Bernasconi, Ulf Forssmann, Rudolf Richter, Berthold Hocher, Andreas Pfützner
Publikováno v:
Kidney & Blood Pressure Research, Vol 41, Iss 5, Pp 507-518 (2016)
Background/Aims: Parathyroid hormone (PTH) derivatives exert pronounced renal and osteoanabolic properties when given intermittently. The current study was performed to assess the pharmacokinetic and pharmacodynamic properties as well as safety of su
Externí odkaz:
https://doaj.org/article/9f915dbf8edd4a99ab8bd75474ba5419
Autor:
Richard N van Zyl-Smit, Kenneth R Chapman, Huib AM Kerstjens, Christian Gessner, Hironori Sagara, Ana-Maria Tanase, Motoi Hosoe, Abhijit Pethe, David Lawrence, Hanns-Christian Tillmann, Peter D'Andrea
Publikováno v:
Journal of Asthma and Allergy. 16:123-134
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Background and Objective Clinical evidence suggests no clinically relevant pharmacokinetic interactions between indacaterol (IND), glycopyrronium (GLY) and mometasone furoate (MF). A population pharmacokinetic (popPK) analysis was conducted to identi
Autor:
Henrik Watz, Ieuan Jones, Hanns Christian Tillmann, Zuzana Diamant, Kenneth R. Chapman, Dave Singh, Ivan Nikolaev, Jens M. Hohlfeld
Publikováno v:
Clinical drug investigation, 41(5), 489-492. ADIS INT LTD
Clinical Drug Investigation
Clinical Drug Investigation
Autor:
Ujjini H. Manjunatha, Natko Nuber, Cynthia L. Chappell, Wilbur H. Chen, Rajiv S. Jumani, Jay Parthiban Lakshman, Richa Chandra, Natasha Aziz, Dean Wetty, Thierry T. Diagana, Johanne Blais, Hanns-Christian Tillmann, Florencia Segal, Christian Ostermeier
Publikováno v:
ACS Infectious Diseases
Cryptosporidiosis is a leading cause of moderate-to-severe diarrhea in low- and middle-income countries, responsible for high mortality in children younger than two years of age, and it is also strongly associated with childhood malnutrition and grow